Dapagliflozin-induced Abnormal Uterine Bleeding in a Patient with Dilated Cardiomyopathy and Chronic Heart Failure: a Case Report

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2024 Aug 24

PMID 39180294

Authors

Shikun Gong

Shunan Zhang

Yun Ye

Meiling Wu

Affiliations

Soon will be listed here.

Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are extensively used in the management of heart failure because of their cardiovascular benefits. Adverse drug reactions associated with dapagliflozin include diabetic ketoacidosis, fungal infections, and increased blood glucose concentrations. However, abnormal uterine bleeding is not a known side effect of dapagliflozin. We report a 75-year-old Chinese woman with dilated cardiomyopathy and chronic heart failure who experienced abnormal uterine bleeding while taking dapagliflozin. Notably, cessation of dapagliflozin administration resulted in the disappearance of uterine bleeding. These findings suggest that dapagliflozin possesses additional potential mechanisms, but these mechanisms require further investigation. Furthermore, healthcare professionals should remain vigilant regarding the occurrence of uterine bleeding when prescribing dapagliflozin.

Citing Articles

A study on the pharmacovigilance of various SGLT-2 inhibitors.

Dong Y, Wang Y, Lan X, Zeng H Front Med (Lausanne). 2025; 11:1515847.

PMID: 39882521 PMC: 11774954. DOI: 10.3389/fmed.2024.1515847.

References

Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. View

Pitt B, Bhatt D, Szarek M, Cannon C, Leiter L, McGuire D . Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF. JACC Heart Fail. 2023; 11(8 Pt 1):879-889. DOI: 10.1016/j.jchf.2023.05.026. View

De Crem N, Peerlinck K, Vanassche T, Vanheule K, Debaveye B, Middeldorp S . Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res. 2015; 136(4):749-53. DOI: 10.1016/j.thromres.2015.07.030. View

Lescano C, Leonardi G, Torres P, Amaral T, de Freitas Filho L, Antunes E . The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation. Biochem Pharmacol. 2020; 182:114276. DOI: 10.1016/j.bcp.2020.114276. View

Chao E . SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clin Diabetes. 2015; 32(1):4-11. PMC: 4521423. DOI: 10.2337/diaclin.32.1.4. View

Packer M, Butler J, Filippatos G, Jamal W, Salsali A, Schnee J . Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019; 21(10):1270-1278. DOI: 10.1002/ejhf.1536. View

Biester T, Aschemeier B, Fath M, Frey M, Scheerer M, Kordonouri O . Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. Diabetes Obes Metab. 2017; 19(11):1635-1639. DOI: 10.1111/dom.12975. View

McMurray J, DeMets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A . A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019; 21(5):665-675. PMC: 6607736. DOI: 10.1002/ejhf.1432. View

Busse D, Tang W, Scheerer M, Danne T, Biester T, Sokolov V . Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus. Br J Clin Pharmacol. 2019; 85(8):1820-1828. PMC: 6624399. DOI: 10.1111/bcp.13981. View

10.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

11.

Kohlmorgen C, Gerfer S, Feldmann K, Twarock S, Hartwig S, Lehr S . Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia. 2021; 64(8):1834-1849. PMC: 8245397. DOI: 10.1007/s00125-021-05498-0. View

12.

Spigoni V, Fantuzzi F, Carubbi C, Pozzi G, Masselli E, Gobbi G . Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol. 2020; 19(1):46. PMC: 7140327. DOI: 10.1186/s12933-020-01016-5. View

13.

Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View

14.

Gagnier J, Kienle G, Altman D, Moher D, Sox H, Riley D . The CARE guidelines: consensus-based clinical case reporting guideline development. J Med Case Rep. 2013; 7:223. PMC: 3844611. DOI: 10.1186/1752-1947-7-223. View

15.

Dhillon S . Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019; 79(10):1135-1146. PMC: 6879440. DOI: 10.1007/s40265-019-01148-3. View

16.

Petrie M, Verma S, Docherty K, Inzucchi S, Anand I, Belohlavek J . Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020; 323(14):1353-1368. PMC: 7157181. DOI: 10.1001/jama.2020.1906. View

17.

Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J . Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017; 21(2):1-218. PMC: 5292646. DOI: 10.3310/hta21020. View